Want to see AU:PNV full AI Analyst Report?
PNV Stock Chart & Stats
AU$1.01
AU$0.01(0.49%)
At close: 4:00 PM EST
AU$1.01
AU$0.01(0.49%)
Day’s Range― - ―
52-Week RangeAU$0.87 - AU$1.67
Previous CloseN/A
Volume733.50K
Average Volume (3M)1.48M
Market Cap
AU$635.58M
Enterprise ValueAU$703.73M
Total Cash (Recent Filing)AU$29.26M
Total Debt (Recent Filing)AU$31.74M
Price to Earnings (P/E)64.3
Beta1.75
Next Earnings
Aug 21, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.56Price Target Upside54.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$183.09M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Product AdoptionConsistent double-digit NovoSorb sales (+26% YoY) and rapid MTX adoption (+193% YoY, broadening to 240+ US accounts) indicate durable clinical acceptance and recurring consumable demand. This underpins sustainable top-line growth as hospital adoption and procedure penetration scale.
Very High Gross Margins And Improving ProfitabilityExceptionally high gross margins (~96%) and materially improved adjusted EBITDA (+82% YoY) demonstrate durable unit economics and operating leverage. With management expecting full‑year margin recovery after a one‑off, the business has structural margin capacity to convert volume growth into sustained profitability.
Expanded Manufacturing Capacity And Regulatory PathwayA qualified facility with ~5x prior capacity plus an active PMA pathway with BARDA creates durable operational and regulatory scaffolding. Greater production scale reduces supply constraints, supports multi‑SKU commercialization, and the regulatory path materially enhances secure access to the US burns market.
Bears Say
Weak Free Cash Flow And Low Cash ConversionFree cash flow deterioration (-34% growth) and an operating‑cash‑to‑net‑income ratio around 0.11 indicate limited cash conversion from reported profits. This structural cash generation gap constrains internal funding for commercialization, can increase reliance on external capital, and raises sensitivity to cash timing risks.
Outpatient Reimbursement Uncertainty (CMS/RCT Requirement)Outpatient channel expansion faces a structural barrier: CMS policy changes likely require a dedicated RCT to secure office reimbursement. That raises multiyear commercialization risk for outpatient volumes and delays realization of significant addressable‑market upside until clinical and payment evidence is accepted.
Lumpy Procedure-driven Demand And Market ComplexitySales are tied to episodic burn and surgical case volumes and face market‑specific tender cycles (e.g., India), producing structural demand volatility and long sales cycles. This lumpy demand profile complicates capacity utilization, revenue predictability, and long‑term planning for commercial scale-up.
Polynovo News
PNV FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest share price was AU$0.86 and its highest was AU$1.67 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is AU$635.58M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 50 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.006.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is 0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of AU$0 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -8.458%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in AU:PNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.56 (54.46% Upside)
AU$1.56 (54.46% Upside)
Blogger Sentiment
Bullish
AU:PNV Sentiment 97%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
11.87%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
PNV Company Deck
PNV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all AU:PNV earnings summariesPNV Stock 12 Month Forecast
Average Price Target
AU$1.56
▲(54.46% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Options Prices
Currently, No data available
---